Kiessling R - Search Results

1

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.

Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K, Masucci GV. Gamzatova Z, et al. Among authors: kiessling r. Tissue Antigens. 2007 Sep;70(3):205-13. doi: 10.1111/j.1399-0039.2007.00875.x. Tissue Antigens. 2007. PMID: 17661908

2

Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.

Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R. Matsuda M, et al. Among authors: kiessling r. J Exp Med. 1994 Dec 1;180(6):2371-6. doi: 10.1084/jem.180.6.2371. J Exp Med. 1994. PMID: 7964510 Free PMC article.

3

Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

Halapi E, Yamamoto Y, Juhlin C, Jeddi-Tehrani M, Grunewald J, Andersson R, Hising C, Masucci G, Mellstedt H, Kiessling R. Halapi E, et al. Among authors: kiessling r. Cancer Immunol Immunother. 1993;36(3):191-7. doi: 10.1007/BF01741091. Cancer Immunol Immunother. 1993. PMID: 8439980 Free PMC article.

4

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Poschke I, et al. Among authors: kiessling r. Cancer Immunol Immunother. 2012 Jun;61(6):827-38. doi: 10.1007/s00262-011-1143-y. Epub 2011 Nov 12. Cancer Immunol Immunother. 2012. PMID: 22080405 Free PMC article.

5

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Kärre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R. Salazar-Onfray F, et al. Among authors: kiessling r. Cancer Res. 1997 Oct 1;57(19):4348-55. Cancer Res. 1997. PMID: 9331097

6

Development of a technology platform for large-scale clinical grade production of DC.

Adamson L, Palmborg A, Svensson A, Lundqvist A, Hansson M, Kiessling R, Masucci G, Mellstedt H, Pisa P. Adamson L, et al. Among authors: kiessling r. Cytotherapy. 2004;6(4):363-71. doi: 10.1080/14653240410004934. Cytotherapy. 2004. PMID: 16146889

7

Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Naganuma H, Halapi E, Masucci G, Hansson M, Wersäll P, Hising C, Venkateswaran S, Mellstedt H, Kiessling R. Naganuma H, et al. Among authors: kiessling r. Med Oncol Tumor Pharmacother. 1992;9(1):25-33. doi: 10.1007/BF02989650. Med Oncol Tumor Pharmacother. 1992. PMID: 1341317

8

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).

Masucci G, Svensson A, Hansson M, Hansson J, Nakazawa T, Salazar F, Petersson M, Kiessling R. Masucci G, et al. Among authors: kiessling r. J Hematother. 1997 Jun;6(3):253-60. doi: 10.1089/scd.1.1997.6.253. J Hematother. 1997. PMID: 9234180 Clinical Trial.

9

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. Pavlenko M, et al. Among authors: kiessling r. Br J Cancer. 2004 Aug 16;91(4):688-94. doi: 10.1038/sj.bjc.6602019. Br J Cancer. 2004. PMID: 15280930 Free PMC article. Clinical Trial.

10

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R. Kono K, et al. Among authors: kiessling r. Eur J Immunol. 1996 Jun;26(6):1308-13. doi: 10.1002/eji.1830260620. Eur J Immunol. 1996. PMID: 8647210

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

320 results

Search Page

Filters